Reshaping the future of clinical science, technology, & data.
VIDA Intelligence combines clinical imaging expertise, AI-powered infrastructure, and validated biomarkers to help life sciences teams turn complex imaging data into trusted insight.
Explore VIDA’s products across the imaging data lifecycle
Advanced Imaging CRO: Digitized trial orchestration ensures quality, efficient site operations, and reliable imaging biomarker endpoints.
Imaging Biomarkers: Transforming medical imaging data into quantitative biomarkers that power discovery and trial decisions.
Companion Diagnostic: Clinical care solutions that empower imaging intelligence to support physicians' treatment decision.
Imaging Technology: Leverage VIDA's unique platform infrastructure to extend the capabilities of pharma, CRO, and other data systems.
VIDA Intelligence delivers value by connecting every stage of the imaging lifecycle, from trial design and image collection to biomarker discovery and clinical decision support.
Site onboarding vs traditional imaging CRO
50%
Faster
High-quality imaging data, captured correctly the first time
90%
Scan Pass Rate
Quantitative imaging provides earlier & regulatory ready insights
5X
More Likely for Approval
The VIDA Intelligence solution ecosystem unifies imaging from clinical trials, research, and real-world data through AI-driven intelligence, transforming how imaging biomarkers accelerate clinical drug development.
Expand Clinical Insight with the VIDA Intelligence
Connect imaging AI capabilities, clinical data, and partner-driven innovation through a unified network built to support more informed decisions.
Bioxydyn offers imaging biomarkers for MRI, spanning respiratory, cancer, neuro, and liver imaging. The company’s proton lung MRI expertise provides oxygen-enhanced MRI (OE-MRI), a method to monitor and measure gas delivery and uptake in the lungs.
Key Advantages
Cross-Vendor Ease
What industry leaders are saying
The use of diverse quantitative imaging endpoints enabled a more comprehensive assessment of the treatment effects of tezepelumab in this population.
